The US influenza diagnostic market size is projected to expand at a substantial CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to the wide prevalence of influenza and other flu diseases in the US.
Influenza, as a type of flu disease, is caused by the influenza virus and is divided into three groups. The three types of influenza virus are Type A, Type B, and Type C, which are distinguished by their surface proteins, neuraminidase (NA), and hemagglutinin (HA). Since influenza is an infectious disease and transmitted through droplets from mouth, it can be easily spread in public places by infected patients, who often serve as disease carriers.
Introduction of increased government programs aiming at facilitating effective diagnosis have made it easier to obtain over-the-counter (OTC) tests that are user-friendly and help in timely diagnosis. For example, in 2018, the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) announced a collaboration with Diassess Inc. and Cue Health, Inc. to create testing kits for influenza diagnosis. Moreover, several OTC medications are also available that are only intended for the use in home care environments, allowing patients to perform self for the screening of the disease infection. As per the deal, Cue Health, Inc. and Diassess Inc. each were agreed to receive USD 14 million from BARDA for the advanced production of diagnostic tests for influenza B and A virus, which were categorized as OTC products.
According to the Centers for Disease Control and Prevention (CDC), people attaining the aged of 65 years and above accounted for 58% of influenza-related hospitalizations in the US in 2018. Moreover, kids, pregnant women, and other groups of patients with a variety of chronic conditions are among those who are at high risk of contracting the flu virus. In April 2020, the CDC confirmed 186 influenza-related pediatric deaths in the country. The organization further stated that in 2019, 49.1% of the pregnant women had received the flu vaccine and 38% received both the flu and the Tdap, which included Tetanus, Diphtheria, and Pertussis vaccines.
Market Segment Insights
Based on test types, the US influenza diagnostic market is divided into RIDT, RT-PCR, cell culture, and others. The RIDT segment is expected to account for a key share of the market in the coming years owing to widely accessible of the testing type, making them easier to diagnose. RDIT is also recommended by World Health Organization (WHO) for influenza diagnosis as it is moderately complex, responsive, precise, and reliable. Meanwhile, cell culture is an old and effective method of diagnosing the flu that normally takes 3 to 10 days to produce accurate results after sampling. Immunoassay kits are another way to diagnose the disease and is expected to be fueled by an increase in immunoassays provided by market players. Becton, Dickinson and Company, for example, provides the BD Veritor Plus device, a wireless immunoassay for the detection of influenza A and B. Due of its integrated program and efficient interpretation of different infectious diseases, this product has reliable outputs of RDITs in terms of sensitivity and specificity.
On the basis of end-users, the market is divided into hospitals, laboratories, and POCT. Due to an increase in the prevalence of the flu diseases in the US, the hospitals segment is projected to hold a large market share in the coming years. According to the CDC, there were 30,453 laboratory-confirmed influenza-related hospitalizations in the US in 2020, accounting for 9% of the population. As a result, this had led to an increase in hospitalization. With advanced technologies developed by market players, the POCT segment is expected to fuel the market growth during the forecast period. For example, bioMerieux SA's BIONEXIA Influenza A+B, a rapid test for the detection of influenza A and B viruses in humans, are using a nasopharyngeal sample, which is an easy-to-use, cost-effective, and reliable POCT product. New technological developments in POCT kits that allow error-free results are expected to boost the market. The real-time PCR technique is often used in laboratory research. Accurate performance, sensitivity, cost-effectiveness, and the opportunity to monitor several samples at once are some of the benefits of this research.
Get Sample Report @ Request For Sample of Influenza Diagnostic Market – US Industry Analysis, Growth, Share, Size, Trends, and Forecast | Growth Market Reports
Key Players Covered in the Report
Alere; 3M Health Care; Meridian Bioscience, Inc., Becton, Dickinson and Company; Quidel Corporation; Meridian Bioscience, Inc.; SA Scientific, Roche Diagnostics Corporation; Thermo Fisher Scientific Inc.; and Sekisui Diagnostics.
About Growth Market Reports:
Growth Market Reports provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. Growth Market Reports has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Contact:
Growth Market Reports
Phone: +1 909 414 1393
Email: sales@growthmarketreports.com
Web: https://growthmarketreports.com
Follow Us: LinkedIn | Twitter
0
